New combo therapy aims to stop liver cancer from coming back
NCT ID NCT07352007
First seen Jan 22, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests whether giving a combination of an immunotherapy drug (sintilimab) and targeted radiation before surgery can help prevent liver cancer from returning. About 110 adults with resectable liver cancer will be randomly assigned to receive either the combination therapy before surgery or surgery alone. After surgery, both groups will continue sintilimab for up to one year. The main goal is to see if the pre-surgery treatment lowers the chance of cancer coming back within three years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ShandongShandong Cancer Hospital and Institute
Jinan, Shandong, China
Conditions
Explore the condition pages connected to this study.